Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

41 results about "Minicircle" patented technology

Minicircles are small (~4kb) circular replicons. They occur naturally in some eukaryotic organelle genomes. In the mitochondria-derived kinetoplast of trypanosomes, minicircles encode guide RNAs for RNA editing . In Amphidinium, the chloroplast genome is made of minicircles that encode chloroplast proteins .

Preparation method of optical waveguide type minicircle resonant cavity humidity sensor coated with TiO2 thin film

The invention belongs to the optical field and the field of micro-nano systems, and particularly relates to a preparation method of an optical waveguide type minicircle resonant cavity humidity sensorcoated with a TiO2 thin film. The optical waveguide type minicircle resonant cavity humidity sensor includes photoetching on an annular resonant cavity, straight waveguide and input and output grating and coating on the TiO2 thin film on a waveguiding structure. By means of the unique ambulatory mode effect of a minicircle resonant cavity prepared on the SOI waveguide, an optical wave performs resonance in a minicircle, the stable resonance phenomenon can be observed by means of a spectrometer, when the relative humidity of the external world changes, a humidity sensitive thin film absorbs water, the resonant cavity refractive index changes, and then an output spectral line observed on the spectrometer performs wave length shift, and measurement of the humidity is completed. Compared withan ordinary humidity sensor, the optical waveguide type minicircle resonant cavity humidity sensor has the advantages of being easy to operate, low in cost, small in volume, short in reaction time, high in flexibility and not prone to electromagnet interference, and therefore the sensor has the extremely high application value.
Owner:ZHONGBEI UNIV

Protective HPV (Human Papilloma Virus) immunoglobulin of yolk (IgY) and application thereof

The invention belongs to the field of biomedicines and particularly relates to an immunoglobulin of yolk (IgY) of HPV (Human Papilloma Virus) L1 recombinant minicircle DNA (DeoxyriboNucleic Acid) andapplication of the IgY in preventing / treating HPV infection, wherein the HPV L1 recombinant minicircle DNA contains an L1 gene fragment of HPV16 and a signal peptide sequence, and is used as a nucleicacid antigen for directly immunizing laying hens to obtain the IgY disclosed by the invention. The biological activity of the IgY obtained by immunizing the laying hens through DNA nucleic acid antigen intramuscular injection is far superior to that of IgY prepared by a general technique (subcutaneous injection of a protein antigen), the antibody titer is higher and the specificity is higher. TheIgY disclosed by the invention can be used for preparing a drug for preventing / treating the HPV infection; a high-activity anti-HPV antibody is inputted into HPV-positive patients by vaginal medication; by combining with a nano-liposome method, an antibody transmembranely enters the cell and directly neutralizes an HPV virus in cells. The IgY disclosed by the invention is of great significance for preventing cervical cancer.
Owner:江苏润洁生物科技有限公司

Nucleic acid vaccine for preventing HPV (human papilloma virus) infection

The invention belongs to the field of biological medicine and particularly relates to an HPV (human papilloma virus) L1 minicircle DNA vaccine and an application of the vaccine to prevention of HPV infection. The HPV L1 minicircle DNA contains a nucleotide sequence of HPV 16 subtype L1 (major capsid protein). Meanwhile, the minicircle DNA has following advantages: 1), the minicircle DNA is not integrated into a host cell genome, cannot induce new mutation and is safer than a virus vector; 2), the minicircle DNA can be amplified massively in engineering bacteria, the preparation technology is simple, and industrial production cost is low; 3), exogenous gene expression is more stable and more efficient as compared with expression of traditional plasmid. The HPV L1 minicircle DNA has great significance for cervical cancer prevention when applied to vaccine preparation.
Owner:江苏润洁生物科技有限公司

Minicircle DNA expression bridging molecules for connecting human and animal target cells with effector cells, and application of minicircle DNA expression bridging molecules

The application relates to a minicircle DNA expression bridging molecules for connecting human and animal target cells with effector cells, and an application of the minicircle DNA expression bridgingmolecules, in particular to a minicircle DNA vector for in vivo expression human-animal cross reaction bispecific antibody(crBsAb). The human-animal bispecific antibody(crBsAb) can combine human or animal target cells, and can also combine human or animal effector cells (T cells or natural killer cells) so as to treat cancer, infection and other diseases. Before clinical testing with medicines, the human-animal cross reaction bispecific antibody is favorable for evaluation of the safety and the validity of bispecific antibody drugs with an animal model, so as to promote development process ofthe medicines. The bridging molecules are completely the same in large animal experimentation and clinical minicircle DNA-gene drugs for human, and the condition that in the prior art, two differenteditions of biology drugs for common-used animal and human can cause difficult result interpretation, is avoided.
Owner:SYNO MINICIRCLE BIOTECH CO LTD

Nonviral minicircle vector carrying SOX gene and construction method therefor

The present invention relates to a non-viral minicircle vector expressing a SOX gene, a stem cell into which the vector is introduced, a pharmaceutical composition for preventing or treating a cartilage disease, including the stem cell, and a method for constructing the vector. The transformation of mesenchymal stem cells with MC / SOX-Trio or MC / SOX-Duo, which is a non-viral minicircle vector according to the present invention, can completely exclude the necessity of expensive growth factors that have been indispensably used in inducing the differentiation of mesenchymal stem cells into chondrocytes. Accordingly, the mesenchymal stem cells transformed therewith, when implanted in vivo, can differentiate into chondrocytes by themselves, and thus have an advantage capable of simplifying the existing complicated steps of culturing cells to induce differentiation and then transplanting the cells.Further, unlike existing vector systems in which antibiotic-resistant genes and other bacteria-derived exogenous genes are simultaneously transferred to cells even after transformation, the vector of the present invention minimizes transfer of unnecessary genes into target cells by allowing two or three SOX genes necessary only for differentiation into chondrocytes to be regulated under one promoter, and thus can be utilized as a non-viral vector system in the most advantageous form for use in clinical application of stem cell-gene therapeutic agents.
Owner:DONGGUK UNIV IND ACADEMIC COOPERATION FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products